相关实验视频

Updated: Jul 20, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

作为非肌肉侵入性膀癌的替代选择的HIVEC:来自高体积中心的经验

Lucas Kastner¹, Constantin Rieger¹, David Pfister¹

¹Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany.

Urologic oncology

|April 23, 2024

概括

超热静脉化疗 (HIVEC) 为膀癌患者提供高无复发生存率. 这种节约膀的治疗显示出良好的无进展生存率,使其成为激进囊切除的可行替代方案.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
在瘤学瘤学.

背景情况:

高风险的非肌肉侵入性膀癌 (NMIBC) 通常用静脉BCG疗法治疗.
激进囊切除术 (RC) 是BCG失败的标准治疗方法,但许多患者不适合或不愿接受.
超热静脉化疗 (HIVEC) 对这些患者来说是一个有前途的膀节省替代方案.

研究的目的:

为了评估HIVEC在BCG衰竭患者的疗效.
为了评估BCG缺乏或禁忌的BCG-naïve患者的HIVEC.
为了确定HIVEC作为NMIBC的膀节约治疗的有效性.

主要方法:

对治疗HIVEC的前60名患者的分析.
治疗方案:每周进行6次诱导会,然后每月进行6次维持会.
监测包括光囊镜,尿细胞学和治疗后3个月和12个月的膀映射.

主要成果:

随访时间中位数为12个月,平均完成了12个HIVEC循环.
一年和两年无复发生存率分别为67%和40%.
2年后无进展生存率 (PFS) 为98%,只有1名患者进展到肌肉侵袭.

结论:

艾滋病毒肺炎表现出高无复发生存率和优秀的2年PFS (98%),在近80%的患者中保持了膀.
艾滋病毒瘤切除术 (HIVEC) 与激进囊切除术 (radical cystectomy) 提供了类似或更好的瘤治疗结果,并提高了耐受性和安全性.
对于那些拒绝或不符合激进囊管切除术的患者来说,HIVEC是一种有价值的替代方案.

关键词:

在BCG中失败.艾滋病毒艾滋病毒艾滋病毒EC HIVEC 在 NMIBC 中,NMIBC 是一个非常重要的机构.膀癌:膀癌是一种癌症.

更多相关视频

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.